Cargando…

CYP17 MspA1 Gene Polymorphism and Breast Cancer Patients According to Age of Onset in Cancer Institute of Iran

BACKGROUND: Exposure to endogenous hormones such as estrogen is known as a lifetime Breast Cancer (BC) risk factor. Polymorphisms in genes that are involved in the steroidogenic process, such as Cytochrome P450c17alpha (CYP17), affect individuals’ susceptibility to BC. In Iran, the highest incident...

Descripción completa

Detalles Bibliográficos
Autores principales: EBRAHIMI, Elmira, SABOKBAR, Tayebeh, ESKANDARIEH, Sharareh, PEYGHAMBARI, Vahideh, SHIRKOOHI, Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439044/
https://www.ncbi.nlm.nih.gov/pubmed/28540271
_version_ 1783237875474628608
author EBRAHIMI, Elmira
SABOKBAR, Tayebeh
ESKANDARIEH, Sharareh
PEYGHAMBARI, Vahideh
SHIRKOOHI, Reza
author_facet EBRAHIMI, Elmira
SABOKBAR, Tayebeh
ESKANDARIEH, Sharareh
PEYGHAMBARI, Vahideh
SHIRKOOHI, Reza
author_sort EBRAHIMI, Elmira
collection PubMed
description BACKGROUND: Exposure to endogenous hormones such as estrogen is known as a lifetime Breast Cancer (BC) risk factor. Polymorphisms in genes that are involved in the steroidogenic process, such as Cytochrome P450c17alpha (CYP17), affect individuals’ susceptibility to BC. In Iran, the highest incident of BC is among young women. This study aimed to find prevalence of Single Nucleotide Polymorphisms (SNPs) in genes such as CYP17 and significant correlation with age-oriented group of breast cancer. METHODS: In 2016, a case series study was conducted on a total population of 205 patients suffering from breast cancer referred to Cancer Institute, Imam Khomeini Hospital Complex, Tehran, Iran. This population consisted of 104 cases less than 40 yr old and 101 cases over 40. The genotype variants of CYP17 MspA1 were determined using PCR, followed by RFLP. The association of CYP17 MspA1 polymorphisms with the risk of BC in two different age groups was evaluated by calculating odds ratio and 95% confidence intervals using unconditional logistic regression. RESULTS: Carriers of at least one A2 allele may have higher risk of developing breast cancer at younger age compared to patients with A1/A1 genotype (Odds Ratio: 1.99, 95% Confidence Interval: 1.11–3.57, P=0.02). CONCLUSION: CYP17gene polymorphisms may have influence on the early onset of breast cancer.
format Online
Article
Text
id pubmed-5439044
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Tehran University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-54390442017-05-24 CYP17 MspA1 Gene Polymorphism and Breast Cancer Patients According to Age of Onset in Cancer Institute of Iran EBRAHIMI, Elmira SABOKBAR, Tayebeh ESKANDARIEH, Sharareh PEYGHAMBARI, Vahideh SHIRKOOHI, Reza Iran J Public Health Original Article BACKGROUND: Exposure to endogenous hormones such as estrogen is known as a lifetime Breast Cancer (BC) risk factor. Polymorphisms in genes that are involved in the steroidogenic process, such as Cytochrome P450c17alpha (CYP17), affect individuals’ susceptibility to BC. In Iran, the highest incident of BC is among young women. This study aimed to find prevalence of Single Nucleotide Polymorphisms (SNPs) in genes such as CYP17 and significant correlation with age-oriented group of breast cancer. METHODS: In 2016, a case series study was conducted on a total population of 205 patients suffering from breast cancer referred to Cancer Institute, Imam Khomeini Hospital Complex, Tehran, Iran. This population consisted of 104 cases less than 40 yr old and 101 cases over 40. The genotype variants of CYP17 MspA1 were determined using PCR, followed by RFLP. The association of CYP17 MspA1 polymorphisms with the risk of BC in two different age groups was evaluated by calculating odds ratio and 95% confidence intervals using unconditional logistic regression. RESULTS: Carriers of at least one A2 allele may have higher risk of developing breast cancer at younger age compared to patients with A1/A1 genotype (Odds Ratio: 1.99, 95% Confidence Interval: 1.11–3.57, P=0.02). CONCLUSION: CYP17gene polymorphisms may have influence on the early onset of breast cancer. Tehran University of Medical Sciences 2017-04 /pmc/articles/PMC5439044/ /pubmed/28540271 Text en Copyright© Iranian Public Health Association & Tehran University of Medical Sciences http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
EBRAHIMI, Elmira
SABOKBAR, Tayebeh
ESKANDARIEH, Sharareh
PEYGHAMBARI, Vahideh
SHIRKOOHI, Reza
CYP17 MspA1 Gene Polymorphism and Breast Cancer Patients According to Age of Onset in Cancer Institute of Iran
title CYP17 MspA1 Gene Polymorphism and Breast Cancer Patients According to Age of Onset in Cancer Institute of Iran
title_full CYP17 MspA1 Gene Polymorphism and Breast Cancer Patients According to Age of Onset in Cancer Institute of Iran
title_fullStr CYP17 MspA1 Gene Polymorphism and Breast Cancer Patients According to Age of Onset in Cancer Institute of Iran
title_full_unstemmed CYP17 MspA1 Gene Polymorphism and Breast Cancer Patients According to Age of Onset in Cancer Institute of Iran
title_short CYP17 MspA1 Gene Polymorphism and Breast Cancer Patients According to Age of Onset in Cancer Institute of Iran
title_sort cyp17 mspa1 gene polymorphism and breast cancer patients according to age of onset in cancer institute of iran
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439044/
https://www.ncbi.nlm.nih.gov/pubmed/28540271
work_keys_str_mv AT ebrahimielmira cyp17mspa1genepolymorphismandbreastcancerpatientsaccordingtoageofonsetincancerinstituteofiran
AT sabokbartayebeh cyp17mspa1genepolymorphismandbreastcancerpatientsaccordingtoageofonsetincancerinstituteofiran
AT eskandariehsharareh cyp17mspa1genepolymorphismandbreastcancerpatientsaccordingtoageofonsetincancerinstituteofiran
AT peyghambarivahideh cyp17mspa1genepolymorphismandbreastcancerpatientsaccordingtoageofonsetincancerinstituteofiran
AT shirkoohireza cyp17mspa1genepolymorphismandbreastcancerpatientsaccordingtoageofonsetincancerinstituteofiran